Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →17
🟡 Moderate
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
96,803
Total Claims
$5.3M
Drug Cost
1,855
Beneficiaries
$2,841
Cost/Patient
Risk Score Breakdown 17/100
Score components are additive. Read full methodology
Peer Comparison vs. 7,404 Physical Medicine and Rehabilitation providers
-100%
Opioid rate vs peers
0.0% vs 20.2% avg
+524%
Cost per patient vs peers
$2,841 vs $455 avg
+367%
Brand preference vs peers
14.7% vs 3.1% avg
🔎 Data Overview
Cost per patient is 524% above the specialty average. Extreme cost outliers may indicate prescribing of unnecessarily expensive brand-name drugs or inappropriate drug utilization.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Brand vs Generic
Brand: 14,179 claims · $3.7M
Generic: 82,465 claims · $1.6M
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 3,201 | $727K |
| Dulaglutide | 465 | $203K |
| Bictegrav/Emtricit/Tenofov Ala | 48 | $194K |
| Rivaroxaban | 525 | $136K |
| Linagliptin | 671 | $125K |
| Lipase/Protease/Amylase | 153 | $95K |
| Fluticasone/Umeclidin/Vilanter | 182 | $86K |
| Empagliflozin | 328 | $85K |
| Adalimumab | 11 | $82K |
| Etanercept | 11 | $80K |
| Atorvastatin Calcium | 5,219 | $68K |
| Dolutegravir Sodium | 29 | $63K |
| Insulin Aspart | 354 | $61K |
| Abacavir/Dolutegravir/Lamivudi | 16 | $61K |
| Semaglutide | 58 | $58K |
Prescribing Profile
Patient Profile
76
Avg Age
59%
Female
3.06
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data